You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 149 No. 8, August 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Plasma {alpha}2-Antiplasmin Activity

Role in the Evaluation and Management of Fibrinolytic States and Other Bleeding Disorders

Eliot C. Williams, MD, PhD

Arch Intern Med. 1989;149(8):1769-1772.


Abstract

• To determine the clinical significance of acquired {alpha}2-antiplasmin deficiency in patients with bleeding disorders, I reviewed the results of assays performed on 184 patients over a 4-year period. Thirty-two evaluable patients had {alpha}2-antiplasmin activity levels of less than 50% of normal (defined as severe deficiency), and 35 patients had levels between 50% and 75% of normal (mild deficiency). Records of these patients and of 32 patients who had normal levels were reviewed. Most patients with severe {alpha}2-antiplasmin deficiency had either liver disease or disseminated intravascular coagulation and/or fibrinolysis, or both. There was a high incidence of severe {alpha}2-antiplasmin deficiency among patients with acute promyelocytic leukemia. Five patients with pathologic bleeding had no identifiable coagulation abnormalities other than {alpha}2-antiplasmin deficiency. The group with severe {alpha}2-antiplasmin deficiency had a significantly higher incidence of life-threatening or fatal bleeding and the most striking laboratory evidence of hyperfibrinolysis. Using the presence of severe {alpha}2-antiplasmin deficiency as an indication for therapy, {varepsilon}-aminocaproic acid treatment was associated with cessation of life-threatening bleeding in 8 of 11 patients.

(Arch Intern Med. 1989;149:1769-1772)



Author Affiliations

From the Departments of Medicine and Pathology and Laboratory Medicine, University of Wisconsin, Madison.


Footnotes

Accepted for publication December 23, 1988.

Reprint requests to Department of Medicine, 1300 University Ave, Madison, WI 53706 (Dr Williams).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fortnightly Review: Disseminated intravascular coagulation: diagnosis and treatment
Baglin
BMJ 1996;312:683-686.
ABSTRACT | FULL TEXT  

The Importance of {alpha}2-Antiplasmin in the Defibrination Syndrome
WOLF
Arch Intern Med 1989;149:1724-1725.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.